Manifestaciones hepatobiliares asociadas a la enfermedad inflamatoria intestinal
DOI:
https://doi.org/10.59093/27112330.91Palabras clave:
enfermedades inflamatorias del intestino, colitis ulcerosa, enfermedad de Crohn, enfermedades hepatobiliares, colangitis esclerosante primaria, enfermedad del hígado graso no alcohólico, enfermedad hepática inducida por sustancias y drogas.Resumen
La enfermedad inflamatoria intestinal (EII) engloba dos entidades, la enfermedad de Crohn (EC) y la colitis ulcerativa (CU), las cuales son enfermedades inmunomediadas, crónicas y recurrentes que, aunque afectan al intestino, pueden ir acompañadas de manifestaciones extraintestinales de tipo hepatobiliar en el 5 % de los casos. Entre ellas, las más frecuentes son la enfermedad por hígado graso no alcohólico (EHGNA), la colelitiasis, la colangitis esclerosante primaria (CEP), la colangitis relacionada con IgG4, la hepatitis autoinmune (HAI), el síndrome de superposición HAI/CEP, así como la lesión hepática inducida por fármacos (DILI); y otras menos frecuentes como la colangitis biliar primaria (CBP), la trombosis de la vena porta, los abscesos hepáticos, la hepatitis granulomatosa, las hepatitis B y C, la reactivación de la hepatitis B por terapia inmunosupresora, y la amiloidosis. Estas manifestaciones hepatobiliares cursan con una fisiopatología similar o inclusive la misma de la EII, en la que participan el sistema inmune innato y adaptativo, alteración de la microbiota (disbiosis), permeabilidad intestinal, factores de riesgo genéticos (comunes para EII y manifestaciones hepatobiliares) y desencadenantes ambientales. La primera manifestación de un trastorno hepatobiliar es la alteración del perfil de función hepática, por lo que el abordaje diagnóstico se debe dirigir a evaluar y monitorizar las enzimas hepáticas y su asociación a algún patrón diferencial de alteración hepatocelular o colestásico, con el fin de tomar decisiones oportunas con respecto a la suspensión, indicación o modificación de algún medicamento, o cualquier otro abordaje que impida o retrase la evolución de la enfermedad hepatobiliar, y al mismo tiempo garantice el control de la EII, mejorando potencialmente el pronóstico de estos pacientes.
Descargas
Referencias bibliográficas
Gaspar R, Branco CC, Macedo G. Liver manifestations and complications in inflammatory bowel disease: A review. World J Hepatol 2021;13:1956-1967. https://doi.org/10.4254/wjh.v13.i12.1956.
Sáez A, Herrero-Fernández B, Gómez-Bris R, Sánchez-Martínez H, González-Granado JM. Pathophysiology of inflammatory bowel disease: Innate immune system. Int J Mol Sci 2023;24:1526. https://doi.org/10.3390/ijms24021526.
Méndez J, Sandoval P, Marcacuzco H, Pérez S, Plata A, Gonzáles-Yovera J. Epidemiología y fenotipo de la enfermedad de Crohn en un hospital de referencia en Lima Perú. Rev Gastroenterol Perú 2020;40:230-237. https://doi.org/10.47892/rgp.2020.403.1122.
Armanie EA, Martínez JO. Generalidades sobre el abordaje medico de la colitis ulcerosa. Gen 2011;65:144-149.
Borowitz SM. The epidemiology of inflammatory bowel disease: Clues to pathogenesis? Front Pediatr 2022;10:1103713. https://doi.org/10.3389/fped.2022.1103713.
McDowell C, Farooq U, Haseeb M. Inflammatory bowel disease. Treasure Island (FL): StatPearls Publishing; 2023. Acceso 15 de abril de 2023. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK470312/.
Lynch WD, Hsu R. Ulcerative colitis. Treasure Island (FL): StatPearls Publishing; 2023. Acceso 15 de abril de 2023. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK459282/.
Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease - Epidemiology, genetics, and pathogenesis. Expert Rev Gastroenterol Hepatol 2019;13:307-317. https://doi.org/10.1080/17474124.2019.1574569.
Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol 2013;19:7327-7340. https://doi.org/10.3748/wjg.v19.i42.7327.
Núñez FP, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol 2022;14:319-337. https://doi.org/10.4254/wjh.v14.i2.319.
Fousekis FS, Theopistos VI, Katsanos KH, Tsianos EV, Christodoulou DK. Hepatobiliary manifestations and complications in inflammatory bowel disease: A review. Gastroenterology Res 2018;11:83-94. https://doi.org/10.14740/gr990w.
Yarur AJ, Czul F, Levy C. Hepatobiliary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2014;20:1655-1667. https://doi.org/10.1097/mib.0000000000000065.
Gibiino G, Sartini A, Gitto S, Binda C, Sbrancia M, Coluccio C, et al. The other side of malnutrition in inflammatory bowel disease (ibd): Non-alcoholic fatty liver disease. Nutrients 2021;13:2772. https://doi.org/10.3390/nu13082772.
Ionescu VA, Gheorghe G, Varlas VN, Stanescu AMA, Diaconu CC. Hepatobiliary impairments in patients with inflammatory bowel diseases: The current approach. Gastroenterol Insights 2023;14:13-26. https://doi.org/10.3390/gastroent14010002.
Navaneethan U. Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterol Rep (Oxf) 2014;2:193-200. https://doi.org/10.1093/gastro/gou036.
Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: Current concepts, treatment, and implications for disease management. Gastroenterology 2021;161:1118-1132. https://doi.org/10.1053/j.gastro.2021.07.042.
Hedin CR, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L, et al. The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis 2019;13:541-554. https://doi.org/10.1093/ecco-jcc/jjy191.
Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013;10:585-595. https://doi.org/10.1038/nrgastro.2013.117.
Cerrillo E, González ES, Bastida G, Nos P. Manifestaciones extraintestinales en la enfermedad inflamatoria intestinal. Medicine 2020;13:618-630. https://doi.org/10.1016/j.med.2020.06.013.
Kim JM, Cheon JH. Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases. Intest Res 2020;18:249-264. https://doi.org/10.5217/ir.2019.00128.
Fine S. Extraintestinal manifestations of inflammatory bowel disease. R I Med J 2022;105:13-19.
Majchrzak K, Dudek P, Talar-Wojnarowska R, Fichna J. Current approach to hepatobiliary manifestations in inflammatory bowel disease. J Physiol Pharmacol 2021;72:657-665. https://doi.org/10.26402/jpp.2021.5.01.
Villalobos-Orozco MW. Alteración de la microbiota intestinal y su relación con enfermedades gastrointestinales y hepatobiliares. Hepatología 2023;4:75-89. https://doi.org/10.52784/27112330.168.
Ohlsson B. Extraintestinal manifestations in irritable bowel syndrome: A systematic review. Therap Adv Gastroenterol 2022;15:17562848221114558. https://doi.org/10.1177/17562848221114558.
Little R, Wine E, Kamath BM, Griffiths AM, Ricciuto A. Gut microbiome in primary sclerosing cholangitis: A review. World J Gastroenterol 2020;26:2768-2780. https://doi.org/10.3748/wjg.v26.i21.2768.
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1982-1992. https://doi.org/10.1097/mib.0000000000000392.
Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008;14:331-337. https://doi.org/10.3748/wjg.14.331.
Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, et al. Liver involvement in inflammatory bowel disease: What should the clinician know? World J Hepatol 2021;13:1534-1551. https://doi.org/10.4254/wjh.v13.i11.1534.
Yaccob A, Mari A. Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease. Frontline Gastroenterol 2019;10:309-315. https://doi.org/10.1136/flgastro-2018-101037.
Silva J, Brito BS, Silva INN, Nóbrega VG, da Silva M, Gomes HDN, et al. Frequency of hepatobiliary manifestations and concomitant liver disease in inflammatory bowel disease patients. Biomed Res Int 2019;2019:7604939. https://doi.org/10.1155/2019/7604939.
Gizard E, Ford AC, Bronowicki J, Peyrin-Biroulet L. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2014;40:3-15. https://doi.org/https://doi.org/10.1111/apt.12794.
Dias E, Andrade P, Lopes S, Gonçalves R, Cardoso P, Gaspar R, et al. Liver biopsy in inflammatory bowel disease patients with sustained abnormal liver function tests: a retrospective single-center study. Ann Hepatol 2023;36:54-60. https://doi.org/10.20524/aog.2023.0761.
Fousekis FS, Katsanos KH, Theopistos VI, Baltayiannis G, Kosmidou M, Glantzounis G, et al. Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study. BMC Gastroenterol 2019;19:48. https://doi.org/10.1186/s12876-019-0967-3.
Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, et al. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021;13:1828-1849. https://doi.org/10.4254/wjh.v13.i12.1828.
Olpin JD, Sjoberg BP, Stilwill SE, Jensen LE, Rezvani M, Shaaban AM. Beyond the bowel: Extraintestinal manifestations of inflammatory bowel disease. Radiographics 2017;37:1135-1160. https://doi.org/10.1148/rg.2017160121.
Özdirik B, Müller T, Wree A, Tacke F, Sigal M. The role of microbiota in primary sclerosing cholangitis and related biliary malignancies. Int J Mol Sci 2021;22:6975. https://doi.org/10.3390/ijms22136975.
Annese V. A review of extraintestinal manifestations and complications of inflammatory bowel disease. Saudi J Med Med Sci 2019;7:66-73. https://doi.org/10.4103/sjmms.sjmms_81_18.
Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: A systematic review and meta-analysis. Gastroenterology 2021;161:1865-1877. https://doi.org/10.1053/j.gastro.2021.08.032.
Knight C, Murray KF. Hepatobiliary associations with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2009;3:681-691. https://doi.org/10.1586/egh.09.53.
Trivedi PJ, Chapman RW. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol 2012;36:420-436. https://doi.org/10.1016/j.clinre.2011.10.007.
Liberal R, Gaspar R, Lopes S, Macedo G. Primary biliary cholangitis in patients with inflammatory bowel disease. Clin Res Hepatol Gastroenterol 2020;44:e5-e9. https://doi.org/10.1016/j.clinre.2019.05.002.
DeFilippis EM, Kumar S. Clinical presentation and outcomes of autoimmune hepatitis in inflammatory bowel disease. Dig Dis Sci 2015;60:2873-2880. https://doi.org/10.1007/s10620-015-3699-4.
Miranda-Bautista J, Menchén L. Adalimumab-induced autoimmune hepatitis in a patient with Crohn's disease. Gastroenterol Hepatol 2019;42:306-307. https://doi.org/10.1016/j.gastrohep.2018.06.006.
Chevaux JB, Bigard MA, Bensenane M, Oussalah A, Jarlot S, Belle A, et al. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol 2009;33:1082-1093. https://doi.org/10.1016/j.gcb.2009.03.021.
Giri S, Agrawal D, Afzalpurkar S, Kasturi S, Gopan A, Sundaram S, et al. Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis. Intest Res 2022;e14. https://doi.org/10.5217/ir.2022.00094.
Kim ES. Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia. Intest Res 2017;15:5-6. https://doi.org/10.5217/ir.2017.15.1.5.
Kucharska M, Daniluk U, Kwiatek-Średzińska KA, Wasilewska N, Filimoniuk A, Jakimiec P, et al. Hepatobiliary manifestations of inflammatory bowel disease in children. Clin Exp Hepatol 2019;5:203-209. https://doi.org/10.5114/ceh.2019.87632.
Lin JN, Lin CL, Lin MC, Lai CH, Lin HH, Kao CH. Pyogenic liver abscess in patients with inflammatory bowel disease: a nationwide cohort study. Liver Int 2016;36:136-144. https://doi.org/10.1111/liv.12875.
Margalit M, Elinav H, Ilan Y, Shalit M. Liver abscess in inflammatory bowel disease: report of two cases and review of the literature. J Gastroenterol Hepatol 2004;19:1338-1342. https://doi.org/10.1111/j.1440-1746.2004.03368.x.
Gaut D, Shull H, Bejjani A, Kahn D. Hepatic abscess in a returning traveler with crohn's disease: Differentiating amebic from pyogenic liver abscess. Case reports in medicine 2018;2018:9593865-9593865. https://doi.org/10.1155/2018/9593865.
Sharma P, Aguilar R, Siddiqui OA, Nader MA. Secondary systemic amyloidosis in inflammatory bowel disease: a nationwide analysis. Ann Gastroenterol 2017;30:504-511. https://doi.org/10.20524/aog.2017.0168.
Sattianayagam PT, Gillmore JD, Pinney JH, Gibbs SDJ, Wechalekar AD, Gilbertson JA, et al. Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci 2013;58:1689-1697. https://doi.org/10.1007/s10620-012-2549-x.
Solís-Herruzo JA, Solís-Muñoz P. Manifestaciones hepatobiliares en la enfermedad inflamatoria intestinal. Rev Esp Enferm Dig 2007;99:525-542.
Filipec-Kanizaj T, Mijic M. Inflammatory bowel disease in liver transplanted patients. World J Gastroenterol 2017;23:3214-3227. https://doi.org/10.3748/wjg.v23.i18.3214.
Kavcar Z, Civan HA, Taskin DG, Hatipoglu SS. Extraintestinal manifestations in children diagnosed with inflammatory bowel disease. Sisli Etfal Hastan Tip Bul 2023;57:73-78. https://doi.org/10.14744/semb.2022.32708.
Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology 2013;58:1392-1400. https://doi.org/10.1002/hep.26454.
Saubermann LJ, Deneau M, Falcone RA, Murray KF, Ali S, Kohli R, et al. Hepatic issues and complications associated with inflammatory bowel disease: A clinical report from the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees. J Pediatr Gastroenterol Nutr 2017;64:639-652. https://doi.org/10.1097/mpg.0000000000001492.
Restellini S, Chazouillères O, Frossard JL. Hepatic manifestations of inflammatory bowel diseases. Liver Int 2017;37:475-489. https://doi.org/10.1111/liv.13265.
Klein M, Núñez P, Bay C, Pizarro C, Sedano R, Quera R. Liver disorders in inflammatory bowel disease. EMJ Hepatol 2020;8:26-32. https://doi.org/10.33590/emjhepatol/20-00040.
Cheng YW, McLean R, Sewell JL, Huang CY, Khalili M. Inflammatory bowel disease type influences development of elevated liver enzymes. JGH Open 2022;6:846-853. https://doi.org/https://doi.org/10.1002/jgh3.12831.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Hepatología
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La política de reconocimiento de autoría de Hepatología se basa en los criterios indicados por el ICMJE para conferir crédito de un trabajo a una persona, a la vez que se le atribuye responsabilidad por la publicación del mismo.
